OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
57
Results
Show all
Save search
Copy query
Show results for
Unknown
(57)
Publication Date
Release Date
2016
(9)
2019
(8)
2020
(7)
2024
(5)
2015
(5)
2018
(4)
2022
(3)
2021
(3)
2017
(3)
2014
(2)
2013
(2)
2010
(2)
2025
(1)
2023
(1)
2011
(1)
2007
(1)
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
β-catenin regulates c-Myc and CDKN1A expression in breast cancer cells.
Not available
S-EPMC4529819
|
biostudies-literature
Cite
Traditional medicine usage among adult women in Ibadan, Nigeria: a cross-sectional study.
Not available
S-EPMC7083039
|
biostudies-literature
Cite
The
BRCA1
Pseudogene Negatively Regulates Antitumor Responses through Inhibition of Innate Immune Defense Mechanisms.
Not available
S-EPMC7969461
|
biostudies-literature
Cite
PTPN2 copper-sensing relays copper level fluctuations into EGFR/CREB activation and associated CTR1 transcriptional repression.
Not available
S-EPMC11322707
|
biostudies-literature
Cite
Challenges and Recommendations for Improving Cancer Research and Practice in Nigeria:
A Qualitative Study With Multi-Stakeholders in Oncology Research and Practice
.
Not available
S-EPMC11539147
|
biostudies-literature
Cite
Breast cancer risk after full-term pregnancies among African women from Nigeria, Cameroon, and Uganda.
Not available
S-EPMC4573769
|
biostudies-literature
Cite
Development of a Breast Cancer Risk Prediction Model for Women in Nigeria.
Not available
S-EPMC6086588
|
biostudies-literature
Cite
Germline variants and somatic mutation signatures of breast cancer across populations of African and European ancestry in the US and Nigeria.
Not available
S-EPMC6851589
|
biostudies-literature
Cite
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Not available
S-EPMC10705575
|
biostudies-literature
Cite
Patient-derived tumor organoids with p53 mutations, and not wild-type p53, are sensitive to synergistic combination PARP inhibitor treatment.
Not available
S-EPMC10922546
|
biostudies-literature
Cite
Previous
page
1 / 6
You're on page
1
page
2
page
3
page
4
page
5
page
6
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets